Related references
Note: Only part of the references are listed.Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China
Lei Liu et al.
DIABETES THERAPY (2023)
Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023
Nuha A. ElSayed et al.
DIABETES CARE (2023)
Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023
Nuha A. ElSayed et al.
DIABETES CARE (2023)
New developments in the prospects for GLP-1 therapy
Stefan Trapp et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial
Domenica M. Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes The SURPASS-5 Randomized Clinical Trial
Dominik Dahl et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Structural and functional diversity among agonist-bound states of the GLP-1 receptor
Brian P. Cary et al.
NATURE CHEMICAL BIOLOGY (2022)
Peptides in the regulation of glucagon secretion
Daniel B. Andersen et al.
PEPTIDES (2022)
Non-peptide agonists and positive allosteric modulators of glucagon-like peptide-1 receptors: Alternative approaches for treatment of Type 2 diabetes
Faisal Malik et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
The therapeutic potential of GLP-1 receptor biased agonism
Ben Jones
BRITISH JOURNAL OF PHARMACOLOGY (2022)
A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes
Mark A. Pirner et al.
DIABETES (2022)
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
Victoria E. R. Parker et al.
DIABETES OBESITY & METABOLISM (2022)
A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor
David A. Griffith et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Structural basis of peptidomimetic agonism revealed by small-molecule GLP-1R agonists Boc5 and WB4-24
Zhaotong Cong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Mahmoud M. Ali et al.
BMC ENDOCRINE DISORDERS (2022)
Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases A Systematic Review and Meta-analysis of Randomized Clinical Trials
Liyun He et al.
JAMA INTERNAL MEDICINE (2022)
Aerobic glycolysis imaging of epileptic foci during the inter-ictal period
Miao Zhang et al.
EBIOMEDICINE (2022)
The efficacy of canagliflozin in diabetes subgroups stratified by data-driven clustering or a supervised machine learning method: a post hoc analysis of canagliflozin clinical trial data
Xiantong Zou et al.
DIABETOLOGIA (2022)
Global burden of type 2 diabetes in adolescents and young adults, 1990-2019: systematic analysis of the Global Burden of Disease Study 2019
Jinchi Xie et al.
BMJ-BRITISH MEDICAL JOURNAL (2022)
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Vivek P. Chavda et al.
MOLECULES (2022)
What's preventing us from curbing the obesity crisis?
[Anonymous]
LANCET DIABETES & ENDOCRINOLOGY (2022)
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
Vanita R. Aroda et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2022)
A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes
Hongwei Jiang et al.
NATURE COMMUNICATIONS (2022)
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies et al.
DIABETES CARE (2022)
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Shweta Urva et al.
LANCET (2022)
Non-canonical β-adrenergic activation of ERK at endosomes
Yonghoon Kwon et al.
NATURE (2022)
A polypill improves secondary prevention of heart attack
H. Vaillant et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)
Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeutics
Liliane El Eid et al.
PHARMACOLOGICAL RESEARCH (2022)
Polypill Strategy in Secondary Cardiovascular Prevention
Jose M. Castellano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
News ways of understanding the complex biology of diabetes using PET
O. Eriksson et al.
NUCLEAR MEDICINE AND BIOLOGY (2021)
HbA(1c) Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
M. Angelyn Bethel et al.
DIABETES CARE (2021)
Polypill with or without Aspirin in Persons without Cardiovascular Disease
S. Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study
Linong Ji et al.
DIABETOLOGIA (2021)
68Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic β-cell and insulinoma
Linlin Li et al.
NUCLEAR MEDICINE AND BIOLOGY (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
K. El et al.
SCIENCE ADVANCES (2021)
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide
Michele Schiavon et al.
DIABETES OBESITY & METABOLISM (2021)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andreas Andersen et al.
DRUGS (2021)
Dendrocalamus latiflorus and its component rutin exhibit glucose-lowering activities by inhibiting hepatic glucose production via AKT activation
Kun Luo et al.
Acta Pharmaceutica Sinica B (2021)
Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor
Francis S. Willard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Novel therapies with precision mechanisms for type 2 diabetes mellitus
Leigh Perreault et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
Amaara Marzook et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Rajaa Nahra et al.
DIABETES CARE (2021)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock et al.
LANCET (2021)
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
Aditi R. Saxena et al.
NATURE MEDICINE (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Abnormalities of Brain White Matter in Type 2 Diabetes Mellitus: A Meta-Analysis of Diffusion Tensor Imaging
Li Huang et al.
FRONTIERS IN AGING NEUROSCIENCE (2021)
Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor
Fenghui Zhao et al.
ELIFE (2021)
G protein-coupled receptors: structure- and function-based drug discovery
Dehua Yang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
Victoria E. R. Parker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2020 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2020)
Activation of the GLP-1 receptor by a non-peptidic agonist
Peishen Zhao et al.
NATURE (2020)
Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review
Ana Baumgartner et al.
PHARMACEUTICS (2020)
A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models
Tito Borner et al.
DIABETES OBESITY & METABOLISM (2020)
Structural basis of Gs and Gi recognition by the human glucagon receptor
Anna Qiao et al.
SCIENCE (2020)
Full-length human GLP-1 receptor structure without orthosteric ligands
Fan Wu et al.
NATURE COMMUNICATIONS (2020)
Integration of whole-body [F-18]FDG PET/MRI with non-targeted metabolomics can provide new insights on tissue-specific insulin resistance in type 2 diabetes
Klev Diamanti et al.
SCIENTIFIC REPORTS (2020)
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Jose Luis Gorriz et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes A Systematic Review and Network Meta-analysis
Apostolos Tsapas et al.
ANNALS OF INTERNAL MEDICINE (2020)
Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
Enrico Longato et al.
CARDIOVASCULAR DIABETOLOGY (2020)
GLP-1R agonists for the treatment of obesity: a patent review (2015-present)
Chunxia Liu et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2020)
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol
Kim M. Gooding et al.
BMC NEPHROLOGY (2020)
Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Tito Borner et al.
CELL REPORTS (2020)
Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing
Stephane Demine et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists
Xin Zhang et al.
MOLECULAR CELL (2020)
GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
Michael A. Nauck et al.
MOLECULAR METABOLISM (2020)
Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes
Okechi S. Oduori et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Takahiro Kawai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells
Zijian Fang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites (Publication with Expression of Concern. See vol. 12, pg. 33348, 2022)
Maorong Wang et al.
RSC ADVANCES (2020)
Accelerating the Throughput of Affinity Mass Spectrometry-Based Ligand Screening toward a G Protein-Coupled Receptor
Yan Lu et al.
ANALYTICAL CHEMISTRY (2019)
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Julio Rosenstock et al.
DIABETES CARE (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
β Cell-intrinsic β-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion
Luiz F. Barella et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Glucagon-like peptide 1 (GLP-1)
T. D. Mueller et al.
MOLECULAR METABOLISM (2019)
Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant
Michelle Khai Khun Yap et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2019)
Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study
Y. L. Zhang et al.
OBESITY SCIENCE & PRACTICE (2019)
Antidiabetic Polypill Improves Central Pathology and Cognitive Impairment in a Mixed Model of Alzheimer's Disease and Type 2 Diabetes
Carmen Infante-Garcia et al.
MOLECULAR NEUROBIOLOGY (2018)
Battle of GLP-1 delivery technologies
Minzhi Yu et al.
ADVANCED DRUG DELIVERY REVIEWS (2018)
Peptide chemistry toolbox - Transforming natural peptides into peptide therapeutics
Milos Erak et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Obesity, metabolic disease and the pancreas-Quantitative imaging of pancreatic fat
Naomi S. Sakai et al.
BRITISH JOURNAL OF RADIOLOGY (2018)
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Tina Vilsboll et al.
DIABETES OBESITY & METABOLISM (2018)
Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO
Jason Bini et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Glucagon-like peptide 1 in health and disease
Andreas Andersen et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Oxyntomodulin: Actions and role in diabetes
Jens J. Holst et al.
PEPTIDES (2018)
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Ben Jones et al.
NATURE COMMUNICATIONS (2018)
Mechanisms of signalling and biased agonism in G protein-coupled receptors
Denise Wootten et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Combined use of polypill components in patients with type 2 diabetes mellitus
Vivi E. Janssen et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
Karolin Bettge et al.
DIABETES OBESITY & METABOLISM (2017)
Structure and Function of Peptide-Binding G Protein-Coupled Receptors
Fan Wu et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion
Makoto Shigeto et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2017)
Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators
Gaojie Song et al.
NATURE (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Extending the Structural View of Class B GPCRs
Chris de Graaf et al.
TRENDS IN BIOCHEMICAL SCIENCES (2017)
β-arrestin-2 is an essential regulator of pancreatic β-cell function under physiological and pathophysiological conditions
Lu Zhu et al.
NATURE COMMUNICATIONS (2017)
Radiomanganese PET Detects Changes in Functional β-Cell Mass in Mouse Models of Diabetes
Reinier Hernandez et al.
DIABETES (2017)
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan Pablo Frias et al.
CELL METABOLISM (2017)
Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
Weena J. Y. Chen et al.
CARDIOVASCULAR DIABETOLOGY (2017)
TCF1 links GIPR signaling to the control of beta cell function and survival
Jonathan E. Campbell et al.
NATURE MEDICINE (2016)
The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema
Stanley S. Schwartz et al.
DIABETES CARE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
Michael A. Nauck et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Oligomerization of a Glucagon-like Peptide 1 Analog: Bridging Experiment and Simulations
Tine M. Frederiksen et al.
BIOPHYSICAL JOURNAL (2015)
Development of a peptide-functionalized imaging nanoprobe for the targeting of (FXYD2)γa as a highly specific biomarker of pancreatic beta cells
Carmen Burtea et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2015)
GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
Makoto Shigeto et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Transformation of Oligomers of Lipidated Peptide Induced by Change in pH
Ying Wang et al.
MOLECULAR PHARMACEUTICS (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Magnetic resonance imaging of diabetic foot complications
Keynes T. A. Low et al.
SINGAPORE MEDICAL JOURNAL (2015)
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Hongkai Zhang et al.
NATURE COMMUNICATIONS (2015)
A Potent α/β-Peptide Analogue of GLP-1 with Prolonged Action in Vivo
Lisa M. Johnson et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
A Polypill Strategy to Improve Adherence Results From the FOCUS Project
Jose M. Castellano et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Real-time trafficking and signaling of the glucagon-like peptide-1 receptor
Sarah Noerklit Roed et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Young-Sun Lee et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment
Amy G. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effect of Patients' Risks and Preferences on Health Gains With Plasma Glucose Level Lowering in Type 2 Diabetes Mellitus
Sandeep Vijan et al.
JAMA INTERNAL MEDICINE (2014)
Glucagon-like peptide-1 receptor-mediated endosomal cAMP generation promotes glucose-stimulated insulin secretion in pancreatic β-cells
Ramya S. Kuna et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Peptide-Polymer Conjugates: From Fundamental Science to Application
Jessica Y. Shu et al.
ANNUAL REVIEW OF PHYSICAL CHEMISTRY, VOL 64 (2013)
Regulation of Insulin Secretion in Human Pancreatic Islets
Patrik Rorsman et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 75 (2013)
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Peter C. Butler et al.
DIABETES CARE (2013)
Hepatic glucose sensing is required to preserve β cell glucose competence
Pascal Seyer et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
Marcus Lind et al.
PRIMARY CARE DIABETES (2012)
Strategies for extended serum half-life of protein therapeutics
Roland E. Kontermann
CURRENT OPINION IN BIOTECHNOLOGY (2011)
Glucose-Dependent Insulinotropic Polypeptide A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
Mikkel Christensen et al.
DIABETES (2011)
From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
Ilaria Dicembrini et al.
EXPERIMENTAL DIABETES RESEARCH (2011)
Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets
Kyle W. Sloop et al.
DIABETES (2010)
GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-Cells
Julie Quoyer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
Takuo Suzuki et al.
JOURNAL OF IMMUNOLOGY (2010)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Passing the baton in class B GPCRs: peptide hormone activation via helix induction?
Christoph Parthier et al.
TRENDS IN BIOCHEMICAL SCIENCES (2009)
Role of the cAMP sensor Epac as a determinant of KATP channel ATP sensitivity in human pancreatic β-cells and rat INS-1 cells
Guoxin Kang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice
Desu Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Small-molecule agonists for the glucagon-like peptide 1 receptor
Lotte Bjerre Knudsen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes
MS Fineman et al.
DIABETES CARE (2003)
CAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2
US Jhala et al.
GENES & DEVELOPMENT (2003)
Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling
A Bavec et al.
REGULATORY PEPTIDES (2003)
Effect of pegylation on pharmaceuticals
JM Harris et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic β-cells
GX Kang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2001)
Share Paper
